AG opines on ‘thorny issue’ in Truvada SPC clash

Advocate General Melchior Wathelet has advised the Court of Justice of the European Union (CJEU) on a case involving a supplementary protection certificate (SPC).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

CJEU clarifies ‘basic patent’ meaning in SPC dispute

25 July 2018 Earlier today, the Court of Justice of the European Union clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of the SPC regulation.

Big Pharma

Swiss Federal Supreme Court to adopt EU SPC case law

28 June 2018 Switzerland’s highest court held that new supplementary protection certificates for combination products should be governed by the relevant EU law, in a dispute over a Swiss SPC owned by Gilead Sciences.

Big Pharma

French court knocks out Gilead Truvada SPC

4 June 2018 The Paris Court of First Instance has nullified a supplementary protection certificate covering Gilead’s HIV/AIDS treatment Truvada.